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Drew J. Schwartz1,2*† , Amy E. Langdon2,3† and Gautam Dantas2,3,4,5*

Abstract
The human gut microbiome is a dynamic collection of bacteria, archaea, fungi, and viruses that performs essential
functions for immune development, pathogen colonization resistance, and food metabolism. Perturbation of the
gut microbiome’s ecological balance, commonly by antibiotics, can cause and exacerbate diseases. To predict and
successfully rescue such perturbations, first, we must understand the underlying taxonomic and functional
dynamics of the microbiome as it changes throughout infancy, childhood, and adulthood. We offer an overview of
the healthy gut bacterial architecture over these life stages and comment on vulnerability to short and long
courses of antibiotics. Second, the resilience of the microbiome after antibiotic perturbation depends on key
characteristics, such as the nature, timing, duration, and spectrum of a course of antibiotics, as well as microbiome
modulatory factors such as age, travel, underlying illness, antibiotic resistance pattern, and diet. In this review, we
discuss acute and chronic antibiotic perturbations to the microbiome and resistome in the context of microbiome
stability and dynamics. We specifically discuss key taxonomic and resistance gene changes that accompany
antibiotic treatment of neonates, children, and adults. Restoration of a healthy gut microbial ecosystem after routine
antibiotics will require rationally managed exposure to specific antibiotics and microbes. To that end, we review the
use of fecal microbiota transplantation and probiotics to direct recolonization of the gut ecosystem. We conclude
with our perspectives on how best to assess, predict, and aid recovery of the microbiome after antibiotic
perturbation.
Keywords: Gut microbiome, Resistome, Antibiotics, Perturbation, Resilience, Dynamics, Recolonization

Introduction
The human gut microbiome consists of bacteria, viruses, and fungi ideally living symbiotically with their
human host, though this review will focus exclusively
on bacterial residents within the gut microbiome [1].
Individual species and collective bacterial functions
within the gut microbiome confer many benefits
throughout life including metabolizing dietary
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contributions, educating the immune system, defending against pathogens, and contributing to overall
health and optimal growth [2–6]. The gut microbiome is affected by and influences pathologies including inflammatory bowel disease (IBD), allergies,
asthma, and neurobehavioral disorders [4, 5, 7, 8].
Another key feature of the microbiome is the quantity, identity, and function of antibiotic resistance
genes (ARGs), collectively called the resistome. ARGs
transmit between species within the gut microbiome
including potential pathogens. Therefore, understanding how the resistome changes in parallel with the
microbiome is vitally important [9, 10]. Accordingly,
numerous avenues of research are being pursued to
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understand what constitutes healthy and abnormal
microbiomes and resistomes.
Current microbiome research is largely concerned
with “who is there?” and “what are they doing?” Microbiome taxonomic profiling is achieved by culturedependent molecular or phenotypic typing or cultureindependent sequencing of taxonomically informative
marker genes or whole metagenomic shotgun sequencing from microbiome samples, within or between individuals [11–14]. Similarly, features and functions of the
microbiome can be assessed by gene-level analysis,
metabolomics, and assessment of the abundance of gene
pathways for microbial metabolic function [15–20].
These analyses are typically conducted in the context of
human development throughout life or in connection
with clinical outcomes [21]. Measures of diversity within
(α) and between (β) samples can be used to compare microbial communities over time and between disease
states (extensively reviewed in [22]). Our ability to
attribute disease associations to causality is difficult and
requires longitudinal, prospective studies, ideally complemented by mechanistic validation in animals [21, 23].
However, important associations between the human
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microbiome structure and function with diseases and
health nevertheless provide meaningful hypotheses and
correlations [7, 21, 24, 25].
The most common external perturbations to the
microbiome are diet, medications (especially antibiotics), and the environment [26–31]. In this review,
we focus on antibiotic perturbation throughout life
and associations with other factors including age and
maturity of the microbiome, diet and the environment, and the co-morbidities of the individual (Fig. 1).
How the microbiome responds to antibiotics is altered by the state of the microbiome at the time of
perturbation (diet, species, and functional diversity
and redundancy) and the strength of the perturbation
(route, spectrum, and duration of antibiotics). After
cessation of antibiotics, the prevalence of beneficial or
potentially pathogenic and/or antibiotic-resistant (AR)
microbes that recolonize the gut microbiome governs
the initial and long-term outcomes of antibiotic treatment (Fig. 1). These factors must be considered individually and collectively when correlating changes in
the microbiome structure and function to human
health and disease.

Fig. 1 Antibiotic perturbation to the microbiome needs to be considered in context. Certain factors are important to consider throughout life
(overarching factors). Other factors such as diet and the functional and species diversity and redundancy are important to consider when the
antibiotic perturbation is applied. The duration, spectrum, and route of antibiotics are vitally important in the context of how the microbiome
responds during an intervention. The post-antibiotic environment including availability and colonization of pathogens, frequency of horizontal
gene transfer (HGT), MDROs, and beneficial microbes is important to consider the resilience and response after antibiotic cessation. These factors
influence the structure and function of the microbiome before, during, and after antibiotics throughout life. Created with BioRender
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Development of the human microbiome
Immediately after birth, bacteria, viruses, and fungi
colonize the sterile human gut with a subsequent rapid
accumulation of species and diversity from the mother
and the environment [32–34]. Gut microbiome richness
and diversity continue to change until 2–3 years of life,
after which the microbiome stabilizes with less dramatic
monthly changes [26, 35]. The neonatal and infant periods, however, are defined by dynamic changes in microbial diversity on a weekly, if not daily, timescale.
Dramatic strain-level changes and interactions shape the
early life microbiome providing essential metabolic and
immune regulatory functions [36, 37]. This increase in
microbial species and functions matures the gut microbiome increasing both its richness and diversity [26, 38].
Determining geographical and environmental developmental baselines and trajectories allows for understanding the effects of perturbations to normal development
[32, 39]. Preterm birth, residence in the neonatal intensive care unit (NICU), malnutrition, and frequent antibiotics can perturb microbiome development and result in
microbiota “age regression” [32, 38, 39]. Microbiota age
regression is indicated by the child’s chronological age
exceeding their age predicted from the constituents of
their microbiome [32, 39]. Thus, comparing a child’s
chronological age with an assessment of microbiota
health from the species composition can provide a gross
understanding of development and disruptions thereof.
The overall diversity and community architecture of
healthy adult microbiomes do not change dramatically
in the absence of significant perturbation [26, 40, 41].
However, among healthy adults, the relative abundance
of specific taxa can change on a daily or weekly scale
[42], but microbial functions are more stable longitudinally [43]. As an important caveat, some of these inferred
differences regarding daily changes may be an erroneous
Table 1 Microbiome methods and limitations
Bias introduced during extraction, amplification, sequencing, and
bioinformatic processing can alter the relative abundances of species
within a sample [44]. Relative abundances can range from 50-fold higher
or lower than actual depending on the specific species contribution and
protocols used [44]. The complete absence of a species may reflect bias
below the limit of detection. Conversely, expansion of specific taxa may
reflect progressive and systemic bias enriching for sequencing reads
from those taxa [44]. It is therefore important to consider and correct for
these biases in any experiment where taxon relative abundance is considered using computational methods [44]. A key step in any metagenomic sequencing experiment is to sequence similar, defined
communities of different taxon proportions to understand bias in each
protocol. Sequencing-defined communities can lead to computational
estimates of protocol bias that can be applied to all samples prior to
analysis [44]. Furthermore, extraction and processing introduce contamination depending on its format, and each kit has its own DNA that
needs to be evaluated especially when considering a potentially sterile
site [45–47]. Thus, sequencing both mock, negative controls of the sequencing kit only and contrived, defined bacterial communities is essential for optimal microbiome sequencing determination.
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result of sequencing error from various sources and
amplification of or depletion of rare and low abundance
taxa (Table 1) [44, 48]. Biases can be both taxa-intrinsic
as well as protocol-specific [44]. For example, among 3
different extraction protocols, the relative abundance of
Clostridioides difficile was universally lower and Fusobacterium nucleatum higher than the actual abundance
of the mock community [44]. Conversely, certain protocols enriched for specific taxa over others in all mock
communities. The range of individual abundances among
replicates varied as much as 10-fold within a given extraction and processing protocol [44]. Therefore, a daily
change in relative abundance could be a result of systematic bias and should be evaluated as such (Table 1).
Although the dichotomy of stable (e.g., healthy adult)
versus dynamic (e.g., developing infant) microbiomes is
likely oversimplified, it is important to understand that
the impact of an intervention/perturbation depends on
the context (Fig. 1). That is, a relatively more stable,
healthy, adult microbiome can resist and rebound faster
and more completely from the same perturbation that
could change the developmental trajectory of a preterm
neonate and leave lasting changes (Fig. 1) [32]. Partly,
this difference relates to the degree of functional diversity and redundancy in the microbiome with different
strains of the same species contributing functions or occupying various distinct and overlapping niches [37, 49].

Acute perturbations to the microbiome and
resistome
Vulnerable infancy

Large-scale studies of the microbiome have demonstrated that the dynamic first 2 years of life respond
most dramatically to antibiotic perturbation [26, 50].
Antibiotic treatment during the first 18 months of life
results in greater disruption than subsequent administration, as measured by β diversity between consecutive
samples [50, 51]. Among the most dynamic periods of
microbiome development is the first 6 months of life
[26, 28]. Prior to birth, intrapartum antibiotic administration to mothers significantly affected the microbiome
structure of 1-month-old neonates relative to control infants even in the absence of continued antibiotic exposure [52, 53] (Table 2). Further, intrapartum antibiotics
lead to persistent enrichment of ARGs in exposed, term
neonates relative to non-treated neonates or their
mothers at 6 months of life [52]. Importantly, in this
study, neither exposed nor the control children were
antibiotic-treated after birth. Therefore, the administration of antibiotics during this critical developmental window can lead to short- and intermediate-term negative
effects on the microbiome and resistome.
An extreme example of this paradigm of microbiome
dynamics is neonates who are born prematurely and
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Table 2 Key findings of summarized work
Authors

Population

General findings

Species and ARGs implicated

Parnanen et al. 2018 [52]

Fecal samples of 16 mother-infant
pairs shotgun metagenomic
sequenced over the first 6 months
of life

Intrapartum antibiotics increased
fetal ARGs and decreased diversity
at 1 month

Efflux pumps and other ARGs mapping
to E. coli and Klebsiella spp. enriched in
antibiotic-exposed subjects

Gibson et al. 2016 [54]

84 NICU-hospitalized
preterm neonates with stool
samples flanking antibiotic
treatment sequenced

Meropenem, cefotaxime, and
ticarcillin-clavulanate decreased
microbiome diversity whereas
gentamicin and vancomycin
had variable effects

Abundance of E. coli and S. aureus and
the two-component regulator system,
cpxR/cpxA predicted gut microbiome
response to vancomycin and gentamicin

Bokulich et al. 2016 [55]

43 infants followed over the first
2 years of life

Antibiotics delayed microbiome
maturation with fewer species
and lower diversity that resolved
after 1 year of life

Relative abundance of Clostridiales
and Ruminococcus decreased from
3 to 9 months in the antibioticexposed group

Palleja et al. 2018 [56]

12 healthy adults treated with 4 days
of meropenem, gentamicin, and
vancomycin with fecal shotgun
metagenomic sequencing for
6 months after

Gut microbiome diversity
recovered after 6 months, but
richness did not; no persistent
enrichment of ARGs

Multi-drug efflux pumps most enriched
immediately after treatment; complete
absence at 6 months of baseline species
belonging to Bifidobacterium, Coprococcus,
and Methanobrevibacter within individuals

Lloyd-Price et al. 2019 [7]

Multi-omic analysis of 132
children and adults with IBD
or controls contributing 2965
specimens

Increased inter-individual
variation during IBD flare;
multi-omic signatures
differentiate dysbiosis from
baseline

Prevotella copri maintained high
relative abundance in Crohn’s disease
patients but fluctuated in its abundance
in controls; dysbiosis marked by decreased
Faecalibacterium prausnitzii and Roseburia
hominis and increased E. coli

Gasparrini et al. 2019 [32]

41 NICU-hospitalized preterm
infants variably exposed to
antibiotics and 17 antibioticnaive near-term infants followed
through 21 months of life

Preterm infant microbiome
exhibited delayed development
with recovery by 15 months

Persistent MDRO Enterobacteriales
colonization in several infants; model
including Prevotella copri, Eubacterium
rectale, Ruminococcus spp., and ARGs 96%
predictive of whether a fecal sample
originated from a preterm, antibioticexposed or near-term antibiotic-naive infant

Yassour et al. 2016 [28]

39 Finnish children aged 2 to
36 months contributing monthly
stool samples

Frequent antibiotic courses
diminished gut microbiome
species and strain diversity
and enriched for ARGs

Antibiotic treatment more drastically
affected the strain-level diversity of
Bacteroides fragilis than Bacteroides
vulgatus; relative abundance of many
ARGs decreased after cessation; others
(CfxA6 beta-lactamase) remained high

Doan et al. [57, 58]

30 children in Niger randomized
to placebo or bi-annual azithromycin
for 2 years

No dramatic effect on microbiome
diversity or relative abundance

Decreased relative abundance of
Campylobacter spp.; increased
macrolide resistance overall and in
S. pneumoniae at 24 months

Suez et al. 2018 [59]

21 healthy adults treated with
7 days of ciprofloxacin and
metronidazole then randomized
to probiotics, autologous FMT,
and spontaneous recovery

FMT accelerated and probiotics
inhibited microbiome structural
and functional recovery

Relative abundance of Enterococcus
casseliflavus and Blatia producta
inversely correlated with overall
microbiome richness

reside in NICUs. Antibiotic treatment of premature infants is both routine and extensive [60–62]. Antibiotic
treatment decreases gut microbial diversity and enriches
for AR potential pathogens [54]. Antibiotics delivered in
the NICU are varied, [63] ranging from relatively shortterm exposure with narrow-spectrum agents such as
ampicillin or cefazolin to long-term exposure with
broad-spectrum agents such as 3rd-generation cephalosporins and carbapenems [54, 64]. The preterm gut
microbiota of NICU-hospitalized neonates is dominated
by Escherichia coli, Klebsiella spp., Enterobacter spp.,
and Enterococcus spp., which are found in the NICU

environment, are often multi-drug resistant, and are
causes of bacteremia in this population [54, 65, 66]
(Table 2). Antibiotic administration in this environment
results in a fundamentally altered and extremely ARGenriched gut microbiome acutely after antibiotics, but
the response to each antibiotic differed based on the
microbiome composition [54]. The overall microbiome
response to gentamicin and vancomycin could be predicted based on the abundance of the species E. coli and
Staphylococcus aureus and the ARGs/bacterial response
regulator cpxA/cpxR [54]. Additionally, members of the
Enterobacteriales harbored hundreds of novel ARGs
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conferring functional resistance to beta-lactams, tetracyclines, and aminoglycosides [54]. Further research investigating the strain-level diversity and functional
evolution over time in the NICU and after discharge is
needed to identify the covariation and consequences of
specific antibiotic therapy in the context of birth history,
diet, and environment for each individual’s microbiome.
Antibiotic treatment in infancy enriches for AR organisms in the stool as determined by selective culturing
and DNA sequencing [32, 54]. To more broadly
characterize novel and unknown resistance mechanisms,
researchers have utilized functional metagenomics,
whereby fecal DNA is cloned into plasmids, introduced
into E. coli, and plated on selective media [32, 54, 67].
These functionally validated ARGs present in the original fecal samples encode for proteins, the majority of
which had not been previously ascribed resistance mechanisms in curated databases [54, 68]. Greater than 40%
of these ARGs derive from E. coli, Enterobacter spp., and
Klebsiella spp., encoding resistance to commonly used
antibiotics in the NICU (penicillins and cephalosporins)
as well as antibiotics not used in the NICU (tetracyclines
and chloramphenicol) [54] (Table 2). A strength of this
approach is that it allows the identification of a broad
range of ARGs assuming expression in E. coli. Accordingly, these novel ARGs are likely still an underestimate
of the total resistome. To date, similar methods have
been unsuccessful in gram-positive bacteria. Resistance
to antimicrobials that exclusively or preferentially target
gram positives such as vancomycin, linezolid, and clindamycin would require other methods to identify. Therefore, frequent antibiotic use during times of microbial
change acutely disturbs the microbiome and enriches for
potential pathogens and ARGs.
Dynamic childhood

Childhood is a time of immense microbiome dynamics and
environmental changes including dietary shifts and introductions [6, 26, 69]. After vulnerable infancy, the microbiome goes through a developmental stage (3–14 months
of age) and a transitional stage (15–30 months) before stabilizing to a near-adult like configuration [26]. Arguably,
the most significant microbiome perturbation during early
childhood is the transition from breastmilk or formula to
solid foods [26, 70]. The pre-weaning microbiome is dominated by Bifidobacterium spp. and, thereafter, several
microbiome states, so-called enterotypes, account for the
bulk of gut community structure [26]. Microbial diversity
of a breastfed child after weaning increases commensurate
with the accumulation and enrichment of strains responsible for dietary metabolism [26, 27, 37]. Transitions between these states accompany chronological aging, likely
reflective of differential environmental exposures including
antibiotics, infections, and diet [26, 55, 69].
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Antibiotic administration during childhood typically
consists of short courses of relatively narrow spectrum
agents for respiratory tract and oropharyngeal infections
[71]. Intermittent postnatal antibiotic exposure was associated with decreased abundance of Clostridiales and
Ruminococcus even though the overall number of species
and diversity was similar between exposed and unexposed groups after 1 year of life (Table 2) [55]. However,
if antibiotics are frequent or in the context of underlying
gastrointestinal disturbances or inadequate diet, their effects can be magnified [55, 72]. Specifically, short
courses of antibiotics were shown to exacerbate dysbiosis from Crohn’s disease [72]. Thus, antibiotics, diet, and
environment acutely impact the developmental trajectory and diversity of the gut microbiome of the developing child.
Stable adulthood

A child’s microbiome achieves an adult-like configuration with less dramatic changes monthly between 2 and
3 years of age [26, 35]. Assuming that the healthy adult
microbiome is completely stable is inaccurate as high
temporal resolution studies have shown variability of different body sites over time [48]. However, individuals
with the greatest Shannon diversity in the gut microbiome had the smallest temporal variability with most
taxa stable over long periods of time in the absence of
perturbation [41, 48]. These findings have ushered in
one of the central dogmas of the microbiome field:
microbiomes with higher diversity are more resilient to
perturbation. For instance, researchers treated 12 men
with 4 days of a cocktail of broad-spectrum antibiotics
(meropenem, gentamicin, and vancomycin) and sequenced their gut microbiome over a 6-month period
[56] (Table 2). Immediately after treatment, Klebsiella
spp., Enterococcus spp., and E. coli increased in abundance, but by 8 days after treatment, no significant differences were observed in these species, suggesting acute
bacterial blooms are short-lived after cessation of antibiotics in this population. Microbial richness and diversity
dramatically decreased, but Shannon diversity progressively recovered in the subsequent 6 months. Although
at the gross community level, the microbiome was restored, the absolute number of species remained significantly lower from baseline samples [56].
Lumping together all antibiotics is an oversimplification as the antibiotic spectrum clearly impacts the response of the gut microbiome (Fig. 1) [73]. Indeed,
computational modeling of the short-term impact of
various antibiotics demonstrates that ciprofloxacin, a
broad-spectrum fluoroquinolone antibiotic, showed
more displacement from microbiome equilibrium than
amoxicillin, a narrow spectrum β-lactam antibiotic [74].
Certain strains of the same species do not recover,
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suggesting potentially lasting consequences. Similarly,
oral cefprozil (a β-lactam antibiotic) altered strain-level
dynamics shifting the dominant strain within each individual [75, 76]. It is likely that some of the
individualization of antibiotic effects on strain-level diversification is due to the copy number variation or expression of specific ARGs [76]. Although certain ARGs
were significantly increased immediately after antibiotic
treatment, reports of lasting ARG changes vary per study
likely reflective of the microbiome composition,
spectrum, and route of antibiotic administration, comorbidities, and other factors (Fig. 1) [56, 75, 76]. However, if a stable microbiome is challenged simultaneously
by changing the environment such as foreign travel to
high infectious burden areas or intensive care admission
and antibiotic treatment, the acute microbiome effects
can be more dramatic [77–79]. These results demonstrate the myriad acute changes to the microbiome and
suggest the remarkable plasticity of the stable adult
microbiome to routine perturbation.
Although the adult microbiome is relatively stable in
healthy adults, the microbiome dynamically changes during acute inflammation of gastrointestinal illnesses such as
IBD [7] (Table 2). In one study, researchers characterized
samples as dysbiotic by computing Bray-Curtis dissimilarity between all samples to a reference set of non-IBD controls. Any samples that scored above the 90th percentile
from the median sample-sample difference from the reference set were termed dysbiotic. Using a multi-omics approach, they identified that 24% of samples from patients
with Crohn’s disease were dysbiotic both metagenomically
and metabolomically, far above the expected 10%
threshold. Similarly, during dysbiotic shifts, patients had
discursions from expected constitution not only of metagenomes and their associated metatranscriptomes and
metabolomes, but also in measurements of inflammation
[7]. Both concurrent and antibiotic use in the prior 6
months correlated with gut dysbiosis further exacerbating
the inter-individual and intra-individual microbiome compositional differences [72, 80]. Thus, acute, antibiotic perturbations to the microbiome have a greater effect on
community structure when the microbiome is dynamically
changing due to inflammation.
Another potentially more dynamic time of microbiome
structure is in the elderly. Indeed, small studies have
shown decreased microbiome diversity in the elderly including decreased Firmicutes and increased Proteobacteria, similar to the neonatal microbiome [81–83]. In
contrast to younger adults, the microbiome was more
variable in its composition when sampled within 3month intervals [83]. One potential explanation for this
finding is the number and diversity of non-antibiotic
medications that have been shown to impact the microbiome [31]. More research needs to be conducted on the
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elderly microbiome in the context of immune senescence, co-morbidities, and infection susceptibility, but
the stability of the human microbiome may decrease at
either extreme of age.

Long-term effects of antibiotic perturbation
depend on microbiome state
Understanding the long-term effects of specific antibiotics
is vital to limiting the negative consequences of AR development and international spread. Despite the overall
stable community structure over time, changes in species
composition may persist even after short antibiotic perturbations to the stable microbiome [56, 75, 84]. The immediate environment of an antibiotic recipient is an
important source of newly introduced microbes [32, 54,
59, 66, 85, 86]. This simple fact deserves a great deal more
attention to ensure reliable, positive long-term outcomes
after perturbations to the gut microbiome. Longer-term
effects are also highly dependent on stage of life and stability of the microbiome (Fig. 1) [26, 28, 32, 50, 87, 88].
Vulnerable infancy and dynamic childhood

Frequent antibiotic use in the NICU delays preterm neonatal microbiome maturation initially, but the microbiota recovers to a similar taxonomic composition to
antibiotic-naive term controls by 15 months of life [32].
Similar microbiome recovery at 4 years of life has been
shown for antibiotic treatment in the first year of life
[69]. Thus, even in periods of extreme microbiome turnover, from a gross, structural level, the microbiome is
still resilient and converges to a similar architecture with
antibiotic-naive infants. Although the overall composition of the microbiome was similar, specific species and
ARGs present up to 2 years later distinguished them
from healthy controls [32] (Table 2). Specifically, multidrug resistant organism (MDRO) Enterobacteriales (E.
coli, Klebsiella spp., and Enterobacter spp.) acquired in
the NICU persisted in the gut microbiome up to 1 year
after NICU discharge with greater than 99.997% identity
between them. Machine learning algorithms classified
fecal samples post-NICU discharge deriving from an
antibiotic-naive or frequently exposed infant with 96%
accuracy [32]. Among the most significant features distinguishing these samples were ARGs including class A
β-lactamases as well as functionally validated ARGs to
piperacillin and tetracycline and members of the order
Clostridiales.
In addition to allowing MDRO potential pathogens to
maintain a foothold within the GI tract, frequent antibiotic exposure in this critical microbiome developmental period diminished strain diversity, enriched for
ARGs, and conferred a less stable composition [28]. Researchers collected monthly stool samples from 39 children from 2 months to 3 years variant in their antibiotic
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usage [28] (Table 2). Twenty of these children received
between 9 and 15 antibiotic courses mainly for otitis
media and respiratory infections. They found that
antibiotic-naive children harbored increased strain-level
diversity of Bacteroides fragilis, a key commensal important for immune education and bacterial tolerance
[28, 89]. Harboring more strains of the same species is
believed to be a component of a resilient microbiome as
well as providing different functions [37, 90, 91]. It is
likely possible to achieve microbiome health and resilience to perturbation either by increased strain-level diversity within a species or by maintenance of a diverse
array of different species. In both instances, this taxonomic diversity leads to functional diversity. Intriguingly,
the authors also speculated that frequent antibiotic
courses could lead to multiple colonization attempts by
beneficial species (e.g., Eubacterium rectale) in lieu of
initial colonization and in vivo evolution. That is, because of frequent antibiotic administration, beneficial
microbes are not surviving and undergoing in vivo adaptation, potentially inhibiting the microbiome plasticity
expected of a healthy, interconnected, adult microbiome
[28, 92]. Consecutive samples from the same individual
on antibiotics were less similar to each other than
antibiotic-naive children. This result is not surprising as
antibiotics are expected to acutely diminish diversity.
However, these children also exhibited dramatically
higher variance in this measurement even when not directly treated with antibiotics. ARGs also increased during antibiotic treatment, not all of which returned to
baseline after antibiotic cessation (Table 2) [28]. Frequent antibiotic courses during childhood can thus lead
to long-term consequences such as increased microbiome variability, decreased strain-level diversity, and increased MDRO potential pathogens. Thus, although the
overall taxonomic structure recovers, specific entities remain in the pediatric microbiome as evidence of prior
antibiotic exposure.
The main arguments against the use of antibiotics in
vulnerable populations are the loss of diversity and selection for AR pathogens, which is especially worrisome
when patients are immunocompromised. Treating the
gut microbiota of children with severe acute malnutrition (SAM) therefore constitutes a special case combining all of the factors. In healthy children older than 2
years, some adult-like stability and resilience to antibiotics should be characteristic. Malnourished children
however exhibit an age-regressed microbiome which is
often lacking taxa of a healthy child or adult [39]. Specifically, the gut microbiome of children with SAM is
enriched for Enterobacteriales and deficient in beneficial
microbes such as Dorea spp. and Faecalibacterium
prausnitzii relative to healthy children living in the same
geographical area [39]. Broad-spectrum antibiotics could
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further deplete microbial defenses and inhibit the immune system. Indeed, the relative abundance of Enterobacteriaceae dramatically increased in children with
SAM during treatment with ampicillin/amoxicillin and
gentamicin [39]. The increase of potential pathogens on
a background of poor microbiome and immune health
could be catastrophic leading to invasive AR bacterial
infections.
The data to address the long-term concerns of antimicrobial treatment of SAM is accumulating in placebocontrolled randomized trials of mass drug administration. Azithromycin and amoxicillin have been trialed to
improve all-cause mortality and SAM in sub-Saharan
Africa [93–95]. Researchers analyzed the gut microbiome profiles of 600 preschool children (average age 32
months) randomized to receive a standard course of oral
azithromycin or placebo every 6 months for 2 years [57]
(Table 2). At the end of the 2-year trial, no statistically
significant differences were present between the groups
in microbial richness, diversity, or phylum-level taxonomic composition. This corroborates the research
above that the gross architecture is not commonly affected by a single course of antibiotics. When delving
deeper into the analysis, the authors discovered a reduction in the relative abundance of 35 species including
Campylobacter spp., which can cause diarrheal illnesses
worldwide [57]. As a trade-off for decreased mortality,
azithromycin increased phenotypic AR of pneumococcus
isolated from the nares from children who completed
the trial [58]. Similarly, ARGs encoding resistance to
macrolides (of which azithromycin is a member) were
enriched in fecal metagenomes from azithromycinexposed children. No other phenotypic resistance in
pneumococcus was significantly different between the
treatment groups, and there were no differences in
genotypic resistance determinants in whole fecal
metagenomes [57, 58] (Table 2).
Amoxicillin is also routinely prescribed for uncomplicated SAM in sub-Saharan Africa; however, similar concerns about the long-term consequences of this practice
abound [96]. To address some of these concerns for
amoxicillin as described above, researchers determined
rates of extended-spectrum beta-lactamase (ESBL)
prevalence in a randomized placebo-controlled trial of
amoxicillin for SAM in Niger [93, 97]. ESBL-expressing
Enterobacteriaceae broadly degrade many β-lactam antibiotics, are rising in global prevalence, are common in
Asia and sub-Saharan Africa, and are listed by the CDC
as serious threats [79, 98, 99]. Amoxicillin prophylaxis
increased the percentage of Nigeran children who harbored ESBL Enterobacteriaceae and were negative at
baseline as determined by selective culturing [97]. This
result suggests either endogenous enrichment of below
the limit of detection Enterobacteriaceae, de novo
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acquisition of an ESBL Enterobacteriaceae, or in vivo
horizontal gene transfer (HGT). Additionally, untreated
siblings of amoxicillin-treated children were more likely
than placebo-controlled siblings to acquire an ESBL Enterobacteriaceae. Therefore, the administration of antibiotics can potentially affect the long-term AR of specific
genera and can lead to environmental dissemination.
However, given the repeated demonstration of their
positive effect on childhood health, we support this practice. Further research demonstrating the environmental
impact of increased AR in this population needs to be
performed.
Stable adulthood

The relatively stable adult microbiome requires more
sensitive measurement techniques to assess long-term
perturbations. Once the microbiome has stabilized
around age 2–3 [26, 35], minimal differences in microbiome stability have been observed between bi-monthly
samples in children treated with various oral antibiotics
[50]. Furthermore, researchers treated 66 healthy adults
with one of four oral antibiotics and collected salivary
and fecal samples 1, 2, 4, and 12 months after exposure
[100]. Although both the fecal and salivary microbiomes
were acutely disrupted by antibiotics as measured by
Bray-Curtis dissimilarity, no differences persisted at 1
year suggesting long-term stability and resilience to perturbation. An alternative explanation, however, is that
the microbiome is meta-stable, and antibiotic perturbation may transition the structure to an alternative, yet
still stable (meta-stable) composition with similar numbers of species and diversity. Indeed, modeling existing
datasets of healthy humans treated with antibiotics supports this assertion [56, 74, 100].
The response to the same antibiotic appears individualized at the taxa level likely reflective of underlying co-morbidities, local environment, or prior
antibiotic history commensurate with ARG abundance
(Fig. 1) [84, 101]. Additionally, the microbiome is
temporally variable in relative abundance even in the
absence of perturbation, but these changes were small
compared to the impact of ciprofloxacin [84]. Specifically, members of the Clostridiales, among the most
abundant pre-ciprofloxacin taxa, were absent in all
samples after treatment [101]. Advanced sequencing
techniques combined with longitudinal sampling will
continue to refine our understanding of the long-term
consequences and changes to the microbiome from
antibiotic and environmental perturbation.

Therapeutics to ameliorate microbiome and
resistome disruption
Antibiotics affect the microbiome and resistome composition, with the degree of perturbation determined by
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many factors (Fig. 1) [28, 55, 59]. Ultimately, if an individual’s microbiome is distorted beyond correction after
antibiotic cessation and treatment of an underlying condition, microbiome repair can be considered [86, 102–
106]. The most common diseases for which this has
been trialed are Clostridioides difficile infection (CDI)
and steroid non-responsive colitis [103, 105, 107]. The
most common microbiota restoration methods are fecal
microbiota transplant (FMT) whereby stools either from
the same individual before disruption (auto) or from a
healthy donor (allo) are introduced orally or via enema
or probiotics. More recent research has investigated
whether FMT can more generally be applied to reduce
ARG and MDRO burden of resistance-rich microbiomes
[108–111]. Multiple case reports have described successful decolonization of MDRO Klebsiella spp., Pseudomonas, and vancomycin-resistant enterococci with alloFMT (reviewed in [110]), though no placebo-controlled
trials have yet been conducted for this express purpose.
Autologous FMT has been proposed as a mechanism to
restore a pre-antibiotic microbiome baseline after disruption [59, 106, 112]. Similarly, probiotics, strains of
beneficial bacteria consumed during or after the intervention, are thought to mitigate some of the negative
consequences of antibiotics on the microbiome [113–
115]. Recently, however, probiotics, autologous FMT,
and spontaneous recovery were evaluated for their impact on microbiome recovery after antibiotics in healthy
volunteers (Table 2) [59]. Twenty-one subjects had their
stool microbiome sampled, then they were treated with
7 days of ciprofloxacin and metronidazole and randomized to twice daily probiotics for 1 month, autologous
FMT from a pre-antibiotic baseline sample, or no treatment. Antibiotics disrupted gut microbiome richness
and diversity and metabolic pathways devoted to sugar,
carbon, and amino acid metabolism [59]. Auto-FMT immediately after antibiotics rapidly corrected this dysbiosis with no difference in Bray-Curtis dissimilarity from
baseline 1 day after FMT. Spontaneous microbiome recovery occurred 21 days after antibiotic cessation. Surprisingly, probiotic administration (a commercially
available 11 species consortium called Bio-25 [116]) delayed and prevented microbiome structural and functional recovery with significant compositional differences
present 5 months after antibiotic cessation. The increased relative abundance of Enterococcus casseliflavus
and Blautia producta correlated with maintained low
species richness [59]. An important caveat to this study
is that the probiotic was administered after antibiotics in
lieu of during treatment which is common in clinical
practice [114]. This probiotic has also not been evaluated for its prevention of antibiotic-associated diarrhea,
and unless the probiotic species are resistant to the administered antibiotics, they would likely be eradicated
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during antibiotic treatment. Thus, autologous FMT accelerated and probiotic administration prevented microbiome recovery after antibiotic administration. Although
probiotic administration is a common practice, these
data suggest this practice may exacerbate microbiome
recovery and requires further study.
Despite the benefits of FMT detailed above, the introduction of fecal microbes into another individual is not
without risk. Recently, two immunocompromised patients became bacteremic with ESBL producing E. coli
derived from donor FMT, one of whom succumbed to
the infection [117]. Accordingly, the FDA has decreed
that all investigational FMT products be screened specifically for MDRO, excluding individuals at higher risk for
MDRO colonization and rejecting donor stools that contain MDRO [118]. One other intriguing point shown in
recent FMT studies is that during the dynamic period of
engraftment, new strains, species, and ARGs appear that
were not detectable in either the donor or the recipient
[86, 105]. The frequency and reproducibility of this effect show that the post-treatment environment remains
a major factor in the ultimate composition of the gut
microbiome (Fig. 1). The sheer number of recent metagenomically sequenced FMT studies with publicly available data makes this phenomenon an excellent candidate
for a meta-analysis. Accordingly, the fate of the microbiome after antibiotic perturbation depends on the environment, resilience, and availability of microbes in the
post-disruption period including FMT or probiotics.

Conclusions and future directions
The state of the microbiome, the duration, route, and
spectrum of antibiotic activity, other co-morbidities, diet,
and post-antibiotic environment all factor into the expected acute and chronic disruption and resilience from
perturbation (Fig. 1) [7, 28, 32, 43, 55, 57, 59, 74]. With
the reduction of sequencing costs and technology
coupled with computational pipelines, we are well poised
to conduct deep and well-controlled studies of the impact of microbiome and resistome changes on human
health. The most important issue for the microbiome
field in general is progression from understanding correlation to identifying causal molecular mechanisms [23,
119, 120]. We are entering an era of personalized microbiome medicine, whereby medications or therapies can
be tailored not only to the human genetic polymorphisms, but also to the specific microbiome constituents
[59, 116]. We can envision in the not too distant future,
antimicrobials and therapies are prescribed for their direct anti-pathogen benefit while simultaneously limiting
collateral damage to the microbiome and resistome [113,
121, 122]. It is naive to assume that such direct agents
will not have their own collateral impacts on microbiome composition [122], but hopefully selective agents
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will be less disruptive overall. The human gut microbiome is intimately linked to human health and disease
[7, 21, 123]. Only through carefully considering the impact of interventions on the microbiome, can we better
treat diseases and improve human health.
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